DCE MRI of prostate cancer

Rose M Berman; Anna M Brown; Silvia D Chang; Sandeep Sankineni; Meet Kadakia; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey

doi:10.1007/s00261-015-0589-3

DCE MRI of prostate cancer

Abdom Radiol (NY). 2016 May;41(5):844-53. doi: 10.1007/s00261-015-0589-3.

Authors

Rose M Berman¹, Anna M Brown^{1

2}, Silvia D Chang³, Sandeep Sankineni¹, Meet Kadakia⁴, Bradford J Wood⁵, Peter A Pinto⁴, Peter L Choyke¹, Baris Turkbey⁶

Affiliations

¹ Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182 Bldg 10, Room B3B85, Bethesda, MD, 20892-1088, USA.
² Duke University School of Medicine, Durham, NC, USA.
³ Department of Radiology, University of British Columbia, Vancouver, BC, Canada.
⁴ Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
⁵ Diagnostic Radiology Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA.
⁶ Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182 Bldg 10, Room B3B85, Bethesda, MD, 20892-1088, USA. turkbeyi@mail.nih.gov.

Abstract

DCE MRI is an established component of multi-parametric MRI of the prostate. The sequence highlights the vascularization of cancerous lesions, allowing readers to corroborate suspicious findings on T2W and DW MRI and to note subtle lesions not visible on the other sequences. In this article, we review the technical aspects, methods of evaluation, limitations, and future perspectives of DCE MRI.

Keywords: DCE MRI; Multi-parametric MRI; Prostate cancer.

Publication types

Review

MeSH terms

Contrast Media*
Diagnosis, Differential
Humans
Image-Guided Biopsy
Magnetic Resonance Imaging / methods*
Male
Prostatic Neoplasms / diagnostic imaging*
Prostatic Neoplasms / pathology

Substances

Contrast Media

Grants and funding

ZIA BC010655-14/Intramural NIH HHS/United States